A paper describing the rationale and design of the APOLLO Phase 3 study was published in BMC Neurology. APOLLO was a randomized, double-blind, placebo-controlled, global study evaluating the efficacy and safety of patisiran, an investigational RNAi therapeutic, in patients with hATTR amyloidosis with polyneuropathy.
Read the paper in BMC Neurology
The post APOLLO Phase 3 Trial Methodology Published in BMC Neurology appeared first on Alnylam.